Savara Stock Forecast, Price & News

Savara (NASDAQ:SVRA) Frequently Asked Questions

Is Savara a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Savara in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Savara stock.
View analyst ratings for Savara or view top-rated stocks.

How has Savara's stock price been impacted by COVID-19 (Coronavirus)?

Savara's stock was trading at $2.36 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, SVRA shares have decreased by 44.9% and is now trading at $1.30.
View which stocks have been most impacted by COVID-19.

When is Savara's next earnings date?

Savara is scheduled to release its next quarterly earnings announcement on Friday, February 11th 2022.
View our earnings forecast for Savara.

How were Savara's earnings last quarter?

Savara Inc (NASDAQ:SVRA) announced its earnings results on Friday, November, 12th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.09) by $0.02.
View Savara's earnings history.

What price target have analysts set for SVRA?

3 brokers have issued 1-year price objectives for Savara's stock. Their forecasts range from $4.00 to $7.00. On average, they expect Savara's share price to reach $5.50 in the next twelve months. This suggests a possible upside of 323.1% from the stock's current price.
View analysts' price targets for Savara or view top-rated stocks among Wall Street analysts.

Who are Savara's key executives?

Savara's management team includes the following people:

• Robert N. Neville, Chairman of the Board, Chief Executive Officer (Age 51)
• Taneli Jouhikainen, President, Chief Operating Officer (Age 51)
• David L. Lowrance, Chief Financial Officer (Age 50)
• Nevan C. Elam, Independent Director (Age 49)
• Richard J. Hawkins, Independent Director (Age 68)
• Joseph S. McCracken Ph.D., Independent Director (Age 64)
• Matthew Pauls J.D., Independent Director (Age 46) (LinkedIn Profile)
• Yuri Pikover, Independent Director (Age 56)

Who are some of Savara's key competitors?

Some companies that are related to Savara include Pharvaris (PHVS), Fulcrum Therapeutics (FULC), Mirum Pharmaceuticals (MIRM), BioXcel Therapeutics (BTAI), LianBio (LIAN), DiaMedica Therapeutics (DMCAF), Y-mAbs Therapeutics (YMAB), VBI Vaccines (VBIV), Relmada Therapeutics (RLMD), Albireo Pharma (ALBO), POINT Biopharma Global (PNT), Chimerix (CMRX), Deciphera Pharmaceuticals (DCPH), SIGA Technologies (SIGA) and Inventiva (IVA).
View all of SVRA's competitors.

What other stocks do shareholders of Savara own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Savara investors own include BioLineRx (BLRX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), CEL-SCI (CVM), Geron (GERN), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), Verastem (VSTM), Agile Therapeutics (AGRX) and Corbus Pharmaceuticals (CRBP).

What is Savara's stock symbol?

Savara trades on the NASDAQ under the ticker symbol "SVRA."

How do I buy shares of Savara?

Shares of SVRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Savara's stock price today?

One share of SVRA stock can currently be purchased for approximately $1.30.

How much money does Savara make?

Savara has a market capitalization of $148.03 million and generates $260 thousand in revenue each year.

What is Savara's official website?

The official website for Savara is www.savarapharma.com.

Where are Savara's headquarters?

Savara is headquartered at 6836 Bee Cave Road Building III Suite 200, AUSTIN TX, 78746.

How can I contact Savara?

Savara's mailing address is 6836 Bee Cave Road Building III Suite 200, AUSTIN TX, 78746. The company can be reached via phone at 512-614-1848, via email at [email protected], or via fax at 858-552-0876.